Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients

Johnson & Johnson completes $3.05 billion acquisition of Halda Therapeutics

The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease

FDA nod to Johnson & Johnson’s AKEEGA for aggressive prostate cancer

Patients with BRCA mutations often face aggressive disease and poor prognosis

Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Johnson & Johnson launches new intraocular lens TECNIS PureSee in India

Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance

Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Johnson & Johnson MedTech India partners with Karkinos to upskill professionals in cancer care

To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform